ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC April 21, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated ES-SCLC April 15, 2026
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Ph 3 Trial of Novel Telomere-Targeting Anticancer Therapy April 15, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Boston Oncology CGT Holding to license Xuanzhu Biopharmaceutical’s Bireociclib and Dirozalkib April 15, 2026
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Ph 1b/2 trial of obrixtamig with pumitamig in ES-SCLC April 15, 2026
Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor–Resistant Advanced NSCLC Presented April 15, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate Zocilurtatug Pelitecan in Combination with Imdelltra April 7, 2026
OS beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of Ph 2 THIO-101 trial in NSCLC reported April 7, 2026
ZEGFROVY® (Sunvozertinib) Shows Antitumor Activity in 1L NSCLC Patients with EGFR PACC or Other Uncommon Mutations March 31, 2026
Ph 1/2 Duravelo-3 trial for zelenectide in NECTIN4-amplified breast cancer and Duravelo-4 trial in NECTIN4-amplified NSCLC to be discontinued; trial design of Duravelo-2 trial to be changed March 24, 2026
Positive Ph 3 Results from WU-KONG28 Study of ZEGFROVY® (Sunvozertinib) vs. Chemo in 1L NSCLC with exon20ins Mutation Announced March 24, 2026
First Patient Dosed in Ph 1/2 Trial of TRI-611 for the Treatment of ALK Positive NSCLC March 24, 2026
Extended long-term survival observed in Ph 2a trial in advanced NSCLC treated with aglatimagene besadenovec (aglatimagene or CAN-2409) March 24, 2026
Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
NMPA Accepts New Drug Applications for Toripalimab Subcutaneous Injection Across 12 Indications March 10, 2026
FDA approves IND application for KST-0651 for Ph 1 trial in Advanced Solid Tumors including pancreatic cancer, CRC, NSCLC, and others March 10, 2026
